

Epidemiological Cutoff Values (ECVs): Their Development and Use

Date	Time	Location
Saturday, January 27	5:00-7:00 PM	The Westin Galleria Dallas, Texas

Topic	Speaker
The mathematical and scientific basis for developing and setting epidemiological cut-offs (ECOFFs)	John D. Turnidge, MD, BS, FRACP, FRCPA, FASM <i>Clinical Advisor Australian Commission on Safety and Quality in Health Care Sydney, NSW, Australia</i>
EUCAST's perspective on the development and use of ECOFFs	Gunnar Kahlmeter <i>Professor of Clinical Bacteriology Head of the EUCAST Development Laboratory EUCAST Technical Data Coordinator Växjö, Sweden</i>
FDA's perspective on the development and use of ECVs	Simone M. Shurland, PhD <i>Microbiology Reviewer Clinical Microbiology Team HFD-520 CDER/OND/OAP/DAIP Silver Spring, MD, USA</i>
Antifungal Susceptibility Testing Committee's perspective on the development and use of ECVs	Shawn R. Lockhart, PhD, D(ABMM) <i>Director, Fungal Reference Laboratory Team Lead, Antifungal Laboratory Mycotic Diseases Branch Centers for Disease Control and Prevention Atlanta, GA, USA</i>
AST SC's perspective on the development and use of ECVs	Matthew A. Wikler, MD, MBA, FIDSA <i>President IDTD Consulting Rancho Santa Fe, CA, USA</i>
Q&A	